Glox Therapeutics develops precision antibiotic therapies built on a proprietary protein bacteriocin engineering platform that selectively eradicates drug‑resistant pathogenic bacteria. Its engineered bacteriocins have potent narrow‑spectrum activity against Gram‑negative AMR pathogens while sparing the wider human microbiome. The company is advancing a pipeline focused on infections associated with high AMR and mortality, including lung infections in people with cystic fibrosis. Glox aims to accelerate discovery and development of these precision antibiotics to address urgent unmet clinical need in CF. The business is built from over 20 years of research at the Universities of Glasgow and Oxford and was founded in 2023. Financially, Glox has received investment and support from the Boehringer Ingelheim Venture Fund and Scottish Enterprise and has previously received grant funding from PACE; it was recently awarded further grant support from the CF AMR Syndicate. Glox Therapeutics is developing a pipeline of engineered precision bacteriocins—protein‑based, narrow‑spectrum antibiotics—designed to selectively eradicate drug‑resistant bacteria without harming the human microbiome. The company’s immediate focus is on therapeutics targeted at Escherichia coli and Klebsiella pneumoniae, including hospital‑ and ventilator‑associated pneumonias. Glox says its platform delivers potent activity against specific pathogens or closely related groups, aiming to address high‑mortality AMR infections. The recent £1M PACE grant will accelerate development of these candidates, enable team expansion, and foster industry collaborations. Glox was founded in 2023 and is built on over 20 years of research at the Universities of Glasgow and Oxford. The company has received investment and support from the Boehringer Ingelheim Venture Fund and Scottish Enterprise. Glox Therapeutics is developing precision antibiotics based on engineered protein bacteriocins that selectively target antibiotic-resistant Gram-negative pathogens. Its platform aims to deliver high potency and specificity against pathogens including Pseudomonas aeruginosa and Klebsiella pneumoniae while preserving patients' microbiomes. The company plans to establish laboratories in Oxford and Glasgow and expand its team to accelerate its bacteriocin development programme. Glox was founded in February 2023 by Prof Daniel Walker and Prof Colin Kleanthous, and Dr James Clark was appointed CEO in April this year. The company announced it has raised £4.3M in seed funding to support lab buildouts and hiring. Its near-term focus is advancing bacteriocin candidates with the first target being P. aeruginosa.

Total raised

$7M

Funding rounds

3

Latest round

Grant

Latest activity

Jan 2025